Malignant Neoplasm of Breast

Oncology
4
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
vinfluninePhase 31 trial
Active Trials
NCT01953003Completed112Est. Jul 2017
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
1
Genomically Directed MonotherapyPhase 21 trial
Active Trials
NCT02101385CompletedEst. Sep 2022
DS
Daiichi SankyoChina - Shanghai
1 program
1
DS-8201aPhase 11 trial
Active Trials
NCT03366428Completed51Est. Feb 2021
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DS-8201aPhase 1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pierre Fabrevinflunine
Vera TherapeuticsGenomically Directed Monotherapy
Daiichi SankyoDS-8201a

Clinical Trials (3)

Total enrollment: 163 patients across 3 trials

Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Start: Sep 2013Est. completion: Jul 2017112 patients
Phase 3Completed
NCT02101385Vera TherapeuticsGenomically Directed Monotherapy

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Start: Apr 2014Est. completion: Sep 2022
Phase 2Completed

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Start: Dec 2017Est. completion: Feb 202151 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space